title: Pulmonary arterial hypertension.
abstract: Pulmonary arterial hypertension (PAH) is a devastating disease with significant disability and mortality, and it has much higher prevalence than previously thought. During the past 15 years, we have witnessed remarkable advances in our understanding of pathogenesis, in diagnostic process and in the development of disease-specific treatments for PAH. Nowadays, the diagnosis is more clearly defined, non-invasive markers of disease severity can be widely applied, and finally we can adopt evidence-based treatment. Newer drugs availability has resulted in radical change in the management of this disease. The article reviews established approaches to evaluation and treatment of this disorder.
authors.affiliation: Dipartimento Medico, U.O. Medicina Ospedale Bassini, Azienda Ospedaliera ICP, Cinisello Balsamo, MI, Italy.
authors.forename: Sheng Chin
authors.initials: SC
authors.lastname: Wu
authors.forename: Sergio
authors.initials: S
authors.lastname: Caravita
authors.forename: Elisabetta
authors.initials: E
authors.lastname: Lisi
authors.forename: Simona
authors.initials: S
authors.lastname: Pierini
authors.forename: Viola
authors.initials: V
authors.lastname: Dadone
authors.forename: Sarah E
authors.initials: SE
authors.lastname: Todd
authors.forename: Francesco
authors.initials: F
authors.lastname: Gentile
authors.forename: Maria Beatrice
authors.initials: MB
authors.lastname: Secchi
mesh_terms: D065128:Endothelin Receptor Antagonists; D006801:Humans; D006976:Hypertension, Pulmonary / Q000175:diagnosis* / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology / Q000601:surgery; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D011379:Prognosis; D011453:Prostaglandins / Q000627:therapeutic use
chemical_list: D065128:Endothelin Receptor Antagonists; D010726:Phosphodiesterase Inhibitors; D011453:Prostaglandins